[1]张宁 王嫱.心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展[J].心血管病学进展,2020,(11):1145-1147.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
　ZHANG Ning,WANG Qiang.Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(11):1145-1147.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
点击复制

心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年11期
页码:
1145-1147
栏目:
综述
出版日期:
2020-11-25

文章信息/Info

Title:
Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance
文章编号:
202005150
作者:
张宁1 王嫱2
宁1 王嫱(1.南京医科大学研究生院,江苏 南京 210000;2.南京医科大学第一附属医院风湿免疫科,江苏 南京 210000)
Author(s):
ZHANG Ning1 ; WANG Qiang2
(1.Nanjing Medical University Graduate School, Nanjing 210000, Jiangsu, China; 2. Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu, China)
关键词:
特发性炎症性肌病; 心脏受累; 心脏磁共振
Keywords:
diopathic inflammatory myopathy;  Cardiac involvement;  Cardiac magnetic resonance
DOI:
10.16806/j.cnki.issn.1004-3934.20.11.000
摘要:
特发性炎症性肌病是一组以近端肌无力肌酶升高为特征的系统性自身免疫性风湿病。心脏受累是其预后不良的主要因素之一，但特发性炎症性肌病心脏受累临床症状隐匿，诊断方法和治疗手段有限，所以早期发现和及时治疗对改善患者预后至关重要。心脏磁共振作为评估心脏结构形态、血管系统、心肌灌注、代谢和功能的无创金标准，对于诊断特发性炎症性肌病心脏受累有重要价值。就心脏磁共振评估特发性炎症性肌病心脏受累的研究进展进行综述。
Abstract:
Idiopathic inflammatory myopathy is a group of systemic autoimmune inflammatory diseases characterized by proximal muscle weakness and increased muscle enzymes. Cardiac involvement is one of the main factors for its poor prognosis, however, the clinical symptoms of cardiac involvement in idiopathic inflammatory myopathy are insidious, and the diagnostic methods and treatment methods are limited. Therefore, early detection and timely treatment are essential to improve the prognosis. Cardiac magnetic resonance, a non-invasive gold standard for evaluating cardiac structural morphology, vascular system, myocardial perfusion, metabolism and function, is valuable for diagnosing cardiac involvement in idiopathic inflammatory myopathy. This article reviews the research progress of cardiac magnetic resonance in evaluating cardiac involvement in idiopathic inflammatory myopathy

参考文献/References:

[1] Diederichsen LP. Cardiovascular involvement in myositis[J]. Curr Opin Rheumatol,2017,29(6):598-603.
[2] Opinc AH,Makowski MA,Lukasik ZM,et al. Cardiovascular complications in patients with idiopathic inflammatory myopathies:does heart matter in idiopathic inflammatory myopathies?[J]. Heart Fail Rev,2019,Dec 23.?DOI: 10.1007/s10741-019-09909-8.Online ahead of print.
[3] Maurer B,Walker UA. Role of MRI in diagnosis and management of idiopathic inflammatory myopathies[J]. Curr Rheumatol Rep,2015,17(11):67.
[4] Mavrogeni SI,Kitas GD,Dimitroulas T,et al. Cardiovascular magnetic resonance in rheumatology:current status and recommendations for use[J]. Int J Cardiol,2016,217:135-148.
[5] Bodor GS,Survant L,Voss EM,et al. Cardiac troponin T composition in normal and regenerating human skeletal muscle[J]. Clin Chem,1997,43(3):476-484.
[6] Lilleker JB,Diederichsen ACP, Jacobsen S,et al. Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies[J]. Rheumatology,2018,57(6):1041-1046.
[7] Kiely PDW. Serum skeletal troponin I in inflammatory muscle disease:relation to creatine kinase,CKMB and cardiac troponin I[J]. Ann Rheum Dis,2000,59(9):750-751.
[8] Vasquez M,Nagel E. Clinical indications for cardiovascular magnetic resonance[J]. Heart,2019,105(22):1755-1762.
[9] Rosenbohm A,Buckert D,Gerischer N,et al. Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography[J]. J Neurol,2015,262(4):949-956.
[10] Kuruvilla S,Adenaw N,Katwal AB,et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy:a systematic review and meta-analysis[J]. Circ Cardiovasc Imaging,2014,7(2):250-258.
[11] Bing R,Dweck MR. Myocardial fibrosis:why image,how to image and clinical implications[J]. Heart,2019,105(23):1832-1840.
[12] 万俊义.心脏磁共振钆对比剂延迟强化的临床意义及判断预后的价值[J]. 中国医学影像技术,2012,28(8):1600-1603.
[13] Rosenbohm A,Buckert D,Gerischer N,et al. Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography[J]. J Neurol,2015,262(4):949-956.
[14] Yu L,Sun J,Sun J,et al. Early detection of myocardial involvement by T1 mapping of cardiac MRI in idiopathic inflammatory myopathy[J]. J Magn Reson Imaging,2018,48(2):415-422.
[15] Huber AT, Bravetti M,Lamy J,et al. Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping[J]. J Cardiovasc Magn Reson,2018,20(1):11.
[16] Guo Q,Wu LM,Wang Z,et al. Early detection of silent myocardial impairment in drug-naive patients with new-onset systemic lupus erythematosus[J]. Arthritis Rheumatol, 2018,70(12):2014-2024.
[17] Rodriguez-Reyna TS,Morelos-Guzman M,Hernandez-Reyes P,et al. Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography[J]. Rheumatology,2015,54(4):647-654.
[18] Greulich S,Mayr A,Kitterer D,et al. Advanced myocardial tissue characterisation by a multi-component CMR protocol in patients with rheumatoid arthritis[J]. Eur Radiol, 2017,27(11):4639-4649.
[19] Roller FC,Harth S,Schneider C,et al. T1, T2 mapping and extracellular volume fraction (ECV):application,value and further perspectives in myocardial inflammation and cardiomyopathies[J]. Rofo,2015,187(9):760-770.
[20] Mewton N,Liu CY,Croisille P,et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2011,57(8):891-903.
[21] Taylor AJ,Salerno M,Dharmakumar R,et al. T1 mapping:basic techniques and clinical applications[J]. JACC Cardiovasc Imaging,2016,9(1):67-81.
[22] Khoo T,Stokes MB,Teo K,et al. Cardiac involvement in idiopathic inflammatory myopathies detected by cardiac magnetic resonance imaging[J]. Clin Rheumatol,2019,38(12):3471-3476.
[23] Muscogiuri G,Suranyi P,Schoepf UJ,et al. Cardiac magnetic resonance T1-mapping of the myocardium[J]. J Thorac Imaging,2018,33(2):71-80.
[24] Puntmann VO,Carr-White G,Jabbour A,et al. T1-mapping and outcome in nonischemic cardiomyopathy:all-cause mortality and heart failure[J]. JACC Cardiovasc Imaging,2016,9(1):40-50.
[25] Haaf P,Garg P,Messroghli DR,et al. Cardiac T1 mapping and extracellular volume(ECV) in clinical practice:a comprehensive review[J]. J Cardiovasc Magn Reson,2017,18(1):89.
[26] Robinson AA,Chow K,Salerno M. Myocardial T1 and ECV measurement[J]. JACC Cardiovasc Imaging,2019,12(11):2332-2344.
[27] Friedrich MG,Sechtem U,Schulz-Menger J,et al. Cardiovascular magnetic resonance in myocarditis:A JACC White Paper[J]. J Am Coll Cardiol,2009,53(17):1475-1487.
[28] Radunski UK,Lund GK,Stehning C,et al. CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging[J]. JACC Cardiovasc Imaging,2014,7(7):667-675.
[29] Ferreira VM,Piechnik SK,Robson MD,et al. Myocardial tissue characterization by magnetic resonance imaging:novel applications of T1 and T2 mapping[J]. J Thorac Imaging, 2014,29(3):147-154.
[30] Hamlin SA,Henry TS,Little BP,et al. Mapping the future of cardiac MR imaging:case-based review of T1 and T2 mapping techniques[J]. Radiographics,2014,34(6):1594-1611.
[31] Mavrogeni S,Schwitter J,van Rossum A,et al. Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases:an appraisal of the diagnostic strengths and limitations of the Lake Louise criteria[J]. Int J Cardiol,2018,252:216-219.
[32] Roy C,Slimani A,de Meester C,et al. Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction[J]. J Cardiovasc Magn Reson,2018,20(1):55.
[33] Giri S,Chung YC,Merchant A,et al. T2 quantification for improved detection of myocardial edema[J]. J Cardiovasc Magn Reson,2009,11(1):56.
[34] Mavrogeni S,Apostolou D,Argyriou P,et al. T1 and T2 Mapping in Cardiology:“Mapping the Obscure Object of Desire”[J]. Cardiology,2017,138(4):207-217.
[35] Seetharam K,Lerakis S. Cardiac magnetic resonance imaging:the future is bright[J]. F1000Res,2019,8:1636.
[36] Michalska-Kasiczak M,Bielecka-Dabrowa A,von Haehling S,et al. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction:an overview[J]. Arch Med Sci,2018,14(4):890-909.
[37] Wang J,Shi K,Xu H,et al. Left ventricular deformation in patients with connective tissue disease:evaluated by 3.0T cardiac magnetic resonance tissue tracking[J]. Sci Rep,2019,9(1):17913.
[38] Ruivo C,Vilela EM,Ladeiras-Lopes R,et al. Myocardial deformation measures by cardiac magnetic resonance tissue tracking in myocarditis:relationship with systolic function and myocardial damage[J]. Rev Port Cardiol,2019,38(11):767-776.

相似文献/References:

[1]邱梦倩 周蕾.心肌标志物在评估特发性炎症性肌病心脏损伤中的价值[J].心血管病学进展,2020,(1):71.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.019]
　QIU Mengqian,ZHOU Lei.Value of Myocardial Markers in Evaluating Cardiac Injury in Idiopathic I nflammatory Myopathies[J].Advances in Cardiovascular Diseases,2020,(11):71.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.019]

备注/Memo

备注/Memo:
收稿日期：2020-05-06

基金项目：江苏省青年医学人才计划（QNRC2016612）

通信作者：王嫱，E-mail： jerrytortoise@163.com

更新日期/Last Update: 2021-02-03